The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Current Landscape of Targeted Therapy in Lung Cancer
Abstract
Lung cancer is the leading cause of cancer mortality worldwide. Comprehensive genomic profiling of lung cancers revealed their genetic heterogeneity and complexity and identified numerous targetable oncogenic driver alterations. These molecular profiling efforts have made it possible to exploit the potential of molecularly targeted therapies. Selection of patients for targeted therapies is becoming biomarker‐driven, where the oncogenic drivers in patient tumors are first identified, and subsequently patients bearing drug‐sensitizing genetic aberrations are matched to the appropriate targeted therapy. Success of this design of clinical trials and practice was first demonstrated in EGFR inhibitor trials in lung cancer and has since been incorporated into subsequent targeted therapy trials including ALK‐, ROS1‐, and BRAF V600E‐targeted therapies. In this review we discuss the current landscape of clinically approved and other promising molecularly targeted approaches for the treatment of lung cancers, the challenges with these approaches, and the strategies that could be deployed to overcome these challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 1×
“3 months, respectively.(49,50) However, dabrafenib plus trametinib combination therapy has shown marked efficacy in a recent clinical trial (NCT01336634), and hence, was recently approved for the treatment of BRAF V600E mutant metastatic NSCLC patients.”
BackgroundThress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Self-citationDistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
Self-citationKim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00614-2 · Cited by 471
Planchard, D., Kim, T. M., Mazieres, J., Quoix, E., Riely, G., Barlesi, F., Souquet, P.-J., Smit, E. F., Groen, H. J. M., Kelly, R. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00077-2 · Cited by 453
Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349
Jänne, P. A., van den Heuvel, M. M., Barlesi, F., Cobo, M., Mazieres, J., Crinò, L., Orlov, S., Blackhall, F., Wolf, J., Garrido, P., et al. (2017) · JAMA · doi:10.1001/jama.2017.3438 · Cited by 335
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3404 · Cited by 131
Research works printed but not linked: 57
- 10.1016/j.phrs.2013.11.002 · DOI · Paper page
- 10.1634/theoncologist.8-4-303 · DOI · Paper page
- 10.1634/theoncologist.10-7-461 · DOI · Paper page
- 10.1200/JCO.2010.33.4235 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-3339 · DOI · Paper page
- 10.1093/annonc/mdw611 · DOI · Paper page
- 10.1200/JCO.2017.35.18_suppl.LBA9007 · DOI
- Sullivan I., 2016, Next‐generation EGFR tyrosine kinase inhibitors for treating EGFR‐mutant lung cancer beyond first line, Front. Med. (Lausanne), 3, 76
- 10.1007/s40265-015-0533-4 · DOI · Paper page
- 10.1186/s13045-016-0290-1 · DOI · Paper page
- 10.1016/j.cell.2007.11.025 · DOI · Paper page
- 10.1002/cpt.653 · DOI
- 10.1016/S1470-2045(12)70344-3 · DOI · Paper page
- 10.1093/annonc/mdw305 · DOI · Paper page
- 10.1200/JCO.2017.35.15_suppl.LBA9008 · doi:10.1200/jco.2017.35.15_suppl.lba9008
- 10.1200/JCO.2016.71.5904 · DOI · Paper page
- 10.1056/NEJMoa1508887 · DOI · Paper page
- 10.1200/JCO.2017.35.15_suppl.9006 · DOI
- 10.1016/j.trecan.2016.05.010 · DOI · Paper page
- 10.1038/nm.3930 · DOI · Paper page
- 10.1634/theoncologist.2013-0095 · DOI · Paper page
- 10.1056/NEJMoa1215530 · DOI · Paper page
- 10.1073/pnas.1522052113 · DOI
- 10.1073/pnas.1515281112 · DOI
- 10.1158/1078-0432.CCR-14-1385 · DOI · Paper page
- 10.1073/pnas.1420785112 · DOI · Paper page
- 10.1158/2159-8290.CD-16-1237 · DOI · Paper page
- Sabari J.K., 2017, Targeting RET‐rearranged lung cancers with multikinase inhibitors, Oncoscience, 4, 23, 10.18632/oncoscience.345 · doi:10.18632/oncoscience.345
- 10.1200/JCO.2016.70.9352 · DOI · Paper page
- 10.1158/1078-0432.CCR-16-1887 · DOI
- 10.1517/13543784.2016.1152261 · DOI
- 10.1136/esmoopen-2015-000023 · DOI · Paper page
- 10.1038/nm.3352 · DOI · Paper page
- 10.1097/01.JTO.0000473485.38553.f0 · DOI · Paper page
- 10.1200/JCO.2017.35.15_suppl.LBA2501 · DOI
- 10.1158/2159-0000.CD-0000-0000 · doi:10.1158/2159-0000.cd-0000-0000
- 10.1177/1758834016670555 · DOI
- 10.1634/theoncologist.2016-0458 · DOI
- 10.1016/S1470-2045(16)30146-2 · DOI · Paper page
- 10.1073/pnas.1610456113 · DOI
- 10.1038/nature14982 · DOI · Paper page
- 10.1073/pnas.1320956111 · DOI
- 10.1016/j.ctrv.2014.02.008 · DOI · Paper page
- 10.1093/annonc/mdh031 · DOI · Paper page
- 10.1016/j.lungcan.2012.01.008 · DOI · Paper page
- 10.1016/j.jtho.2016.06.004 · DOI · Paper page
- 10.1158/2159-8290.CD-14-1467 · DOI · Paper page
- 10.1016/j.jtho.2016.10.014 · DOI · Paper page
- 10.1016/j.jtho.2016.06.013 · DOI · Paper page
- 10.1016/j.jtho.2016.09.119 · DOI
- 10.1016/j.jtho.2016.09.127 · DOI
- 10.1158/2159-8290.CD-16-0686 · DOI · Paper page
- 10.1002/cpt.552 · DOI
- 10.1177/1753465816670498 · DOI
- 10.1097/JTO.0000000000000113 · DOI
- 10.1016/j.celrep.2015.03.012 · DOI · Paper page
- 10.1016/S0140-6736(16)00004-0 · DOI · Paper page
Cited by
The lung microenvironment: an important regulator of tumour growth and metastasis
Altorki, N. K., Markowitz, G. J., Gao, D., Port, J. L., Saxena, A., Stiles, B., McGraw, T., & Mittal, V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0081-9 · Cited by 1,150
Nasim, F., Sabath, B. F., & Eapen, G. A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.12.006 · Cited by 829
Deep learning in cancer pathology: a new generation of clinical biomarkers
Echle, A., Rindtorff, N. T., Brinker, T. J., Luedde, T., Pearson, A. T., & Kather, J. N. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01122-x · Cited by 667
Pan-cancer integrative histology-genomic analysis via multimodal deep learning
Chen, R. J., Lu, M. Y., Williamson, D. F. K., Chen, T. Y., Lipkova, J., Noor, Z., Shaban, M., Shady, M., Williams, M., Joo, B., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.004 · Cited by 660
Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer
Chaft, J. E., Rimner, A., Weder, W., Azzoli, C. G., Kris, M. G., & Cascone, T. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00501-4 · Cited by 375
Metadata
- Authors
- Mayekar, M. K., & Bivona, T. G.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2017-09-25
- Volume
- 102
- Issue
- 5
- Pages
- 757-764
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2743605523
- Cited by
- 183
- References
- 18
- FWCI
- 14.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.